Gene and cell therapy using cell fusion technology
AssigneeCuramys Inc.
InventorsJung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.
Claims6
A method for alleviating a symptom of a degenerative muscular disease, comprising:
- administering to a subject a therapeutically effective dose of mesenchymal stem cells transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins by an intramuscular route to damaged muscle cells of a subject in need thereof,
- wherein the symptom is weakness of muscles.
Dependencies are inferred from the claim text.